U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07301008) titled 'Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US' on Oct. 20.
Brief Summary: Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman >= 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress l...